Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

CUR - Neuralstem Inc.

Previous close
0.416
0   0%

Share volume: 500
Last Updated: Fri 01 Mar 2024 06:00:00 AM CET
Biotechnology: -0.86%

PREVIOUS CLOSE
CHG
CHG%
$0.42
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 33%
Dept financing 15%
Liquidity 25%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.42
P/E Ratio 
N/A
DAY RANGE
$0.39 - $0.44
EPS 
-$7.70
52 WEEK RANGE
$1.10 - $13.77
52 WEEK CHANGE
-$86.18
MARKET CAP 
4.010 M
YIELD 
N/A
SHARES OUTSTANDING 
2.638 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$2,480,610
AVERAGE 10 VOLUME 
$3,983,227
AVERAGE 30 VOLUME 
$1,413,245
Company detail
CEO: Kenneth C. Carter
Region: US
Website: http://www.neuralstem.com
Employees: 6
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Biotechnology
Sector: Health Technology

Neuralstem, Inc. operates as a biopharmaceutical company, which engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. Its pipeline includes NSI-189 small molecule program, NSI-566 stem cell therapy program, and novel & proprietary chemical entity screening platform. The company was founded by I. Richard Garr, Karl Y. Johe, and Merrill Solomon in 1996 and is headquartered in Germantown, MD.

Recent news